Newsletter | July 29, 2025

07.29.25 -- Tackling Antimicrobial Resistance With Precision Targeting

FEATURED EDITORIAL

Tackling Antimicrobial Resistance With Precision Targeting

A conversation with Gregory G. Mario and Ajit K. Parhi, Ph.D., TAXIS Pharmaceuticals

TAXIS Pharmaceuticals is developing therapies to combat antimicrobial resistance. We caught up with the company's CEO and CSO to discuss their approach to early R&D.

INDUSTRY INSIGHTS

Transfer Of Fed-Batch To Semi-Perfusion Process

Application Note | By Sabrina Janoschek, Markus Schulze, Gerben Zijlstra, Gerhard Greller, and Jens Matuszczyk, Sartorius

Boost quality, yield, and savings by transitioning from fed-batch to perfusion using a small bioreactor system. Compare performance and optimize cell culture conditions.

Identify Lead Solid Form Early To Reduce Timelines And Downstream Costs

Q&A | Lonza

Devoting early-phase resources for solid form understanding and screening during a drug’s development lifecycle is critical, as doing so can help save time and resources on the path to market.

Increasing Bioavailability With Amorphous Solid Dosage Formulations

White Paper | Lonza

Discover the challenges associated with pH-dependent solubility for oral tyrosine kinase inhibitor drugs and how leveraging ASD formulation can help create more effective, patient-friendly drug products.

Overcoming Limitations To Achieve Uniform Dosing

Case Study | By Tracy Milburn, Cambrex

An immediate need for lower dose capsules in the clinic posed several challenges in blend formulation with very tight timelines for delivery.

SOLUTIONS

Parenteral Formulation Development

Singota Solutions

CD34+ HSC LNP Kits

Cytiva